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Summary
 
Until now, it has been unclear whether murine cytomegalovirus (MCMV)-encoded protein
m144 directly regulates natural killer (NK) cell effector function and whether the effects of
m144 are only strictly evident in the context of MCMV infection. We have generated clones
of the transporter associated with antigen processing (TAP)-2–deficient RMA-S T lymphoma
cell line and its parent cell line, RMA, that stably express significant and equivalent levels of
m144. In vivo NK cell–mediated rejection of RMA-S-m144 lymphomas was reduced com-
pared with rejection of parental or mock-transfected RMA-S clones, indicating the ability of
m144 to regulate NK cell–mediated responses in vivo. Significantly, the accumulation of NK
cells in the peritoneum was reduced in mice challenged with RMA-S-m144, as was the lytic
activity of NK cells recovered from the peritoneum. Expression of m144 on RMA-S cells also
conferred resistance to cytotoxicity mediated in vitro by interleukin 2–activated adherent
spleen NK cells. In summary, the data demonstrate that m144 confers some protection from
NK cell effector function mediated in the absence of target cell class I expression, but that in
vivo the major effect of m144 is to regulate NK cell accumulation and activation at the site of
immune challenge.
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N
 
atural killer (NK) cells play an important role in the early
defense against herpesvirus infection (1–3). In humans,
patients with NK cell deficiencies demonstrate increased
susceptibility to herpesvirus infections, such as human CMV
(HCMV)
 
1
 
 (4). The mechanisms of NK cell–mediated pro-
tection against herpesvirus infection have been well charac-
terized in the murine CMV (MCMV) model; NK-deficient
animals are highly susceptible to MCMV infection, and in
vivo transfer of NK cells confers protection. In addition, the
autosomal dominant non-H gene, designated Cmv-1, regu-
lates MCMV replication through the action of NK cells (1).
The ability of herpesviruses to persist lifelong in infected
individuals suggests that these viruses possess mechanisms
for evading the host protective immune response (5–7). In-
deed, recent studies have characterized several herpesvirus
immune-evasion strategies, in particular the downregula-
tion of host MHC class I expression (6, 7). This process en-
ables evasion of CTL-mediated immune responses, but po-
tentially would leave infected cells more vulnerable to NK
cell–mediated lysis.
MCMV and HCMV genomes each encode a homo-
logue of MHC class I heavy chains, designated m144 and
UL18, respectively (8–10). Although both m144 and UL18
bind 
 
b
 
2-microglobulin like their cellular counterpart, only
UL18 has been shown to mimic class I in the binding of
endogenous peptides (9). The inability of m144 to bind en-
dogenous peptides may be due to a deletion within the
m144 
 
a
 
-2 domain encoding the predicted peptide-binding
groove (10). We have previously demonstrated that a re-
combinant MCMV with a disrupted m144 open reading
frame (
 
D
 
m144) has severely restricted replication during
acute infection compared with wild-type MCMV (11).
Depletion of lymphocyte subsets in infected mice showed
that 
 
D
 
m144 was cleared in vivo in an NK cell–dependent
manner (11), suggesting that m144 may be regulating NK
cell activation and/or effector responses.
It has been hypothesized that m144 mimics the host class
I molecules and thereby acts as a decoy for NK cells by en-
gaging NK cell inhibitory receptors, thus protecting in-
 
1
 
Abbreviations used in this paper:
 
 B6, C57BL/6; HCMV, human CMV;
LIR, leukocyte Ig-like receptor; MCMV, murine CMV; P
 
0
 
, perforin-defi-
cient; RAG, recombination activating gene; TAP, transporter associated
with antigen processing. 
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fected cells from NK cell–mediated lysis (9, 11, 12). A non-
classical MHC class I molecule, HLA-E, has been shown to
inhibit NK cell–mediated cytotoxicity by interaction with
the CD94/NKG2A inhibitory receptor (13, 14), while an-
other, HLA-G, was demonstrated to inhibit NK cell–medi-
ated lysis by interaction with KIR2DL4 (15). More recently,
murine CD1.1, a nonpolymorphic nonclassical MHC class
I–like molecule, has been shown to negatively regulate NK
cell activity (16).
To date, a direct interaction between m144 and NK cell
surface ligands has not been established, nor has the m144
ligand been isolated. Expression of m144 in the human cell
line Raji offered these targets some protection from xeno-
geneic antibody-dependent cellular cytotoxicity (17). To
address whether m144 could directly inhibit NK cell effec-
tor function and/or NK cell activation in a syngeneic
model, we have transfected m144 into a mouse class I–defi-
cient lymphoma. Here we demonstrate that m144 can con-
fer protection to syngeneic lymphoma cells from activated
NK cell–mediated lysis in vitro and in vivo. Furthermore,
we provide the first evidence that the accumulation and ac-
tivation of NK cells in vivo can also be compromised by
cellular expression of m144.
 
Materials and Methods
 
Mice.
 
Inbred C57BL/6 (B6) and BALB/c mice were pur-
chased from The Walter and Eliza Hall Institute of Medical Re-
search, Melbourne, Australia. B6 perforin-deficient (B6.P
 
0
 
) mice
(18) were obtained from Dr. Guna Karupiah, John Curtin School
of Medical Research, Canberra, Australia. B6 recombination ac-
tivating gene (RAG)-1–deficient (B6.RAG-1
 
0
 
) mice were pro-
vided by Dr. Lynn Corcoran, The Walter and Eliza Hall Institute
of Medical Research. Mice 4–6 wk of age were used. All experi-
ments were performed according to animal experimental ethics
committee guidelines.
 
Cell Culture and Reagents.
 
The YAC-1 (H-2
 
a
 
) and RMA (H-2
 
b
 
)
lymphoma cell lines and RMA-S (H-2
 
b
 
) mutant lymphoma (de-
rived from the Rauscher virus–induced murine cell line RBL-5
and defective for peptide loading of MHC class I molecules) were
grown in RPMI medium supplemented with 10% (vol/vol) FCS,
2 mM glutamine,100 U/ml penicillin, and 100 
 
m
 
g/ml streptomy-
cin (GIBCO BRL). RMA-S/RMA-m144 transfectants were grown
in complete RPMI medium with 800 
 
m
 
g/ml G418 (GIBCO
BRL). Recombinant human IL-2 was provided by Chiron Corp.
Adherent IL-2–activated NK cells were generated by culturing
splenocytes in complete RPMI medium with 1,000 U/ml IL-2 for
a minimum of 7 d. These populations were generally 
 
.
 
60%
NK1.1
 
1
 
 (data not shown). Spleens from B6.RAG-1
 
0
 
 mice were
additionally used as a source of NK cell effector cells. In some ex-
periments, NK cell cultures were derived by harvesting spleen cells
from B6 mice and depleting Thy-1.2
 
1
 
 cells using anti–Thy-1.2
mAb (rat IgG2a) and C
 
9
 
 (rabbit 1:30 dilution) before culture in
IL-2 as described (19). Mouse CD8
 
1
 
 CTLs reactive with the hu-
man papilloma virus 16 E7 peptide (RAHYNIVTF) were gener-
ated as described previously (20).
 
Stable Transfection of m144 into Lymphoma Cell Lines.
 
A pCDNA-
m144 construct encoding full-length COOH-terminal c-myc–
tagged MCMV m144 was constructed. RMA or RMA-S cells
were transfected with CsCl-purified pCDNA-m144-tag vector
 
DNA by electroporation (250 V, 960 
 
m
 
F; BioRad Gene Pulser).
Cells (5 
 
3 
 
10
 
6
 
) in RPMI were added to 25 
 
m
 
g of vector DNA in
4-mm cuvettes. After electroporation, cells were added to sup-
plemented RPMI and aliquoted into a 96-well plate. 2 d later,
the medium was removed from the cells and new medium with
800 
 
m
 
g/ml G418 was added to select for transfected cells. After
1 wk in selection medium, cells were replenished with fresh se-
lection medium and viable clones were tested for m144 cell sur-
face expression by flow cytometry and Western analysis.
 
51
 
Cr-release Assays.
 
Direct cytotoxicity of resting and IL-2–
activated spleen NK cells or CTLs reactive with the E7 peptide
was assessed by 4-h 
 
51
 
Cr-release assays against labeled target cells.
For CTL assays, temperature-induced RMA-S or RMA-S-m144
cells were incubated at 25
 
8
 
C for 24 h and then with E7
 
49–57
 
 or
control chicken OVA
 
257–264
 
 (SIINFEKL) peptide for 2–4 h at
33
 
8
 
C as described (20). In some experiments,
 
 51
 
Cr-labeled
RMA-S or RMA-S-m144 cells and unlabeled RMA-S-m144 tar-
get cells (at various E/T ratios) were added to IL-2–activated spleen
NK cells. In all experiments, the spontaneous release of 
 
51
 
Cr was
determined by incubating the target cells (2 
 
3
 
 10
 
4
 
) with medium
alone, while the maximum release was determined by adding
SDS at a final concentration of 5%. The percent specific lysis was
calculated as follows: 100 
 
3
 
 [(experimental release 
 
2
 
 spontane-
ous release)/(maximum release 
 
2 
 
spontaneous release)]. Each ex-
periment was performed at least twice using triplicate samples.
 
Flow Cytometry.
 
RMA-S/RMA and their transfectants were
phenotyped by flow cytometry using a FACStar
 
PLUS™
 
 (Becton
Dickinson). The following mAbs were provided as indicated:
anti–H-2K
 
b
 
D
 
b
 
 (Dr. P. Xing, The Austin Research Institute);
anti-m144 (15C6; Dr. T. Chapman, California Institute of Tech-
nology, Pasadena, CA); and anti–Ly-49A (YE132), C (5E6), D
(4E5), G2 (4D11), and I (5E6) (Dr. J. Ortaldo, Frederick Cancer
Research and Development Center, Frederick, MD). Anti-
NK1.1 (PK136), anti–ICAM-1 (3E2), anti-CD1d (1B1), anti-
CD11a (M17/4), anti-CD80 (1G10), and anti-CD86 (GL1) mAbs
were purchased from PharMingen. Anti–mouse CD3 (29B) was
purchased from Sigma Chemical Co. Cells were incubated at 4
 
8
 
C
(30 min) with primary antibody, washed, and stained with FITC
anti–mouse Ig F(ab
 
9
 
)
 
2
 
 purchased from Silenus.
 
Western Analysis.
 
MCMV m144 expression was measured by
Western analysis. Cells (2 
 
3
 
 10
 
5
 
) were lysed in 70 
 
m
 
l of ice-cold
NP-40 lysis buffer (25 mM Hepes, pH 7, 250 mM NaCl, 2.5 mM
EDTA, 0.1% NP-40, 0.5 mM dithiothreitol, and 2 mM 4-(2-
aminoethyl)-benzenesulfonyl fluoride hydrochloride [AEBSF])
for 30 min at 4
 
8
 
C. Insoluble material was removed by centrifuga-
tion at 4
 
8
 
C. The proteins were separated on 10% SDS-PAGE,
blotted onto Immobilon-P (Millipore Corp.), and visualized by
ECL chemiluminescence (Nycomed Amersham plc).
 
Tumor Growth.
 
Groups of five B6 or B6.P
 
0 
 
mice were injected
with 10
 
1
 
–10
 
5
 
 RMA-S, RMA, RMA-S-m144, RMA-m144, or
RMA-S-neo cells intraperitoneally and monitored daily for tu-
mor ascites development indicated by swelling of the abdomen or
loss of 
 
.
 
20% body weight. Mice were culled when these obvious
signs of tumor growth were noted, and those surviving beyond
100 d were deemed tumor free.
 
NK Cell Accumulation in the Peritoneum after Tumor Challenge.
 
The number of NK1.1
 
1
 
 cells accumulating in the peritoneum
was evaluated in B6 mice that had received intraperitoneal PBS
(0.2 ml), RMA-S, or RMA-S-m144 tumor cells (10
 
3
 
) as described
previously (21). After 72 h, mice were killed by CO
 
2
 
 asphyxia-
tion and their peritoneal cavities were flushed with 0.5 ml com-
plete RPMI and aspirated with a syringe. The percentage of NK
cells recovered was determined by staining with FITC-labeled 
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anti-NK1.1 (PK136; relative to a negative control), and an abso-
lute number of NK1.1
 
1
 
 cells was calculated on the basis of simul-
taneously obtained cell count. The NK cell cytotoxicity mediated
by NK cells recovered from the peritoneum was measured against
YAC-1 target cells after culturing effector cells overnight with
IL-2 (1,000 U/ml). The results were recorded as LU
 
20
 
/10
 
7
 
 cells,
where one LU is the number of effector cells required to lyse
20% of the target cells.
 
Results
 
Expression of m144 in Murine RMA and RMA-S T Lym-
phoma Cells.
 
The murine T cell lymphoma RMA and its
class I–deficient mutant RMA-S were transfected with
m144-tag cDNA, and several transfectants expressing m144
were obtained. Flow cytometric analysis confirmed that
equivalent levels of surface m144 expression were obtained
in both RMA and RMA-S cell lines (Fig. 1, A and B). As
expected, RMA cells expressed high levels of class I, whereas
the RMA-S cells expressed low, but nonfunctional, class I
levels. Expression of m144 did not alter endogenous MHC
class I levels, since parental cell lines and their m144 trans-
fectants expressed similar levels of H-2
 
b
 
 (RMA-S, mean
channel fluorescence [MCF] 
 
5 
 
36.3 
 
6 
 
5.1; RMA-S-m144,
MCF 
 
5 
 
38.3 
 
6 
 
7.2;
 
 n 
 
5 
 
8; Fig. 1, C and D). The expres-
sion of other cell surface molecules that regulate cell–cell
interactions (e.g., CD1d, CD11a, and ICAM-1) were also
shown to be the same in parental cells and their transfec-
tants, while these cells did not express CD80 or CD86
(data not shown). Expression of m144 in the transfectants
was further verified by Western analysis (Fig. 2 A) with the
demonstration of an 
 
z
 
63-kD protein carrying 
 
z
 
18 kD of
 
glycosylation that could be removed by tunicamycin treat-
ment (1 
 
m
 
g/ml overnight). This treatment reduced the size
of m144 to 
 
z
 
45 kD (Fig. 2 B). In all in vitro and in vivo
experiments discussed below, several m144 clones were ex-
amined, and the results presented are representative.
 
m144 Protection of Class I–deficient Lymphoma In Vivo.
 
The class I–deficient lymphoma RMA-S is rejected from
syngeneic mice in a perforin-dependent manner by NK
cells (21, 22). To investigate whether m144 can confer re-
sistance to NK cell–mediated rejection, B6 mice were in-
jected intraperitoneally with increasing doses (10
 
1
 
–10
 
5
 
) of
RMA-S, RMA-S-m144, or RMA-S-neo (transfectant that
lost m144 expression but retained neo resistance) lymphoma
cells. Compared with RMA-S or RMA-S-neo cells, at least
10-fold less RMA-S-m144 cells were required to establish
tumor growth, suggesting that m144 confers resistance to
NK cell–mediated tumor rejection (Fig. 3 A). For example,
all B6 mice injected with 10
 
3
 
 RMA-S-m144 cells died
within 55 d, whereas RMA-S– or RMA-S-neo–injected
mice remained tumor free. Recovery and flow cytometry
evaluation of lymphoma ascites from mice that succumbed
to RMA-S-m144 inoculation indicated that m144-express-
ing tumor cells had retained surface expression of m144 in
five of six mice examined, and all of these tumors still ex-
pressed m144 by Western analysis (data not shown). To
demonstrate that m144 was specifically protecting the lym-
phoma cells from perforin-mediated cytotoxicity, B6.P
 
0
 
mice were examined for their ability to reject lymphoma.
In B6.P
 
0
 
 mice, regardless of the dose of tumor cells admin-
istered, the rejection of RMA-S, RMA-S-neo, and RMA-
S-m144 lymphoma cells was equivalent (Fig. 3 B). The
specificity of the m144 protection against NK cell–medi-
ated responses was demonstrated by the equivalent rejec-
tion of class I–expressing RMA and RMA-m144 cells in
B6 and B6.P
 
0
 
 mice (data not shown). In summary, these in
vivo tumor rejection assays indicated for the first time that
MCMV m144 has the potential to regulate a cellular im-
mune response even when expressed in isolation from
other MCMV genes.
 
Defective Accumulation and Activation of NK Cells in Response
to RMA-S-m144 Inoculation.
 
From previous studies (21), it
was known that NK cell accumulation in the peritoneum
Figure 1. Surface expression of
MCMV m144 and MHC class I
(H-2b) in parental and m144-
transfected lymphomas. (A) RMA,
(B) RMA-S, (C) RMA-m144,
and (D) RMA-S-m144. Isotype
control mAb (solid line), anti-
m144 15C6 mAb (dotted line),
and anti–H-2KbDb mAb (dashed
line). Cells were incubated at 48C
(30 min) with primary antibody,
washed, and stained with FITC
anti–mouse Ig F(ab9)2 before anal-
ysis by flow cytometry. These
profiles were representative of
more than five independent
RMA-m144 and RMA-S-m144
clones.
Figure 2. Western analysis
of m144 expression in RMA-
m144 and RMA-S-m144
transfectants. (A) Parental
lymphoma cell lines (lanes 1
and 2) compared with RMA-
m144 and RMA-S-m144
transfectants (lanes 3 and 4)
when probed with anti-m144
15C6 mAb. The m144 pro-
tein migrated broadly at
z57–63 kD. (B) Tunicamycin
treatment (1 mg/ml overnight)
reduced the m144 migrating species to one band at z45–47 kD. Proteins
were separated by SDS-PAGE and detected by Western analysis as de-
scribed in Materials and Methods. The positions of the protein standards are
shown in kD. These profiles were representative of at least three indepen-
dent RMA-m144 and RMA-S-m144 clones. 
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was maximal after 
 
z
 
3 d in an effective response regardless
of the number of RMA-S tumor cells inoculated. To fur-
ther investigate how MCMV m144 might modulate NK
cell–mediated clearance of class I–deficient lymphomas, B6
mice were inoculated intraperitoneally with PBS, RMA-S
(10
 
3
 
), or RMA-S-m144 (10
 
3
 
) cells. 3 d later, the total num-
ber of leukocytes and NK1.1
 
1
 
 cells accumulated in the
peritoneum was assessed (Fig. 4). Interestingly, although
the total number of leukocytes was increased in mice inoc-
ulated with either tumor, there was comparatively a 30%
reduction in RMA-S-m144–inoculated mice. Even more
strikingly, RMA-S-m144–inoculated mice had a twofold
lower number of NK1.1
 
1
 
 cells accumulated in the perito-
neum compared with RMA-S–inoculated mice, suggesting
that expression of m144 on RMA-S lymphoma cells re-
duced NK cell accumulation at the tumor site. Next we
examined the NK cell lytic capacity of the recovered peri-
toneal cells (cultured in IL-2 overnight) against YAC-1 tar-
gets. Clearly, the peritoneal cells from RMA-S-m144–inoc-
ulated mice were sixfold less cytotoxic than those from
RMA-S–inoculated mice (Fig. 4). Even when taking into
account the twofold decrease in peritoneal NK cells from
RMA-S-m144–inoculated mice, on a per NK cell basis the
lytic activity of NK cells in mice inoculated with RMA-
S-m144 was reduced approximately threefold compared
with mice challenged with RMA-S. It is not clear why the
lytic potential of NK cells from RMA-S-m144–inoculated
mice was reduced nor why IL-2 stimulation overnight was
insufficient to restore cytotoxicity. Further efforts to purify
peritoneal NK cells from tumor-inoculated mice and acti-
vate their lytic program may reveal whether NK cell acti-
vation is suboptimal in the presence of m144.
 
MCMV m144 Protected RMA-S Target Cells from Synge-
neic NK Cell–mediated Cytotoxicity.
 
Since it had previously
been suggested that m144 could directly inhibit NK cell–
mediated cytotoxicity in vitro (17), we evaluated the sensi-
tivity of RMA-S-m144 and RMA-m144 target cells to cy-
tolysis induced by syngeneic B6 NK cells. In agreement
with Ljunggren et al. (23), resting and IL-2–activated
spleen NK cells lysed class I–deficient RMA-S cells effi-
ciently, whereas class I–expressing RMA cells were only
lysed to a minimal extent (Fig. 5, A and B). RMA-S-m144
transfectants were relatively less sensitive (
 
z
 
50%) than
RMA-S cells to IL-2–activated NK cells, whereas RMA-
m144 and RMA were lysed to the same extent (Fig. 5 B).
Surprisingly, RMA-S-m144 transfectants were not more
resistant to lysis mediated by resting NK cells (Fig. 5 A),
suggesting that activation of the spleen NK cell population
Figure 3. m144 expression reduces the elimination of intraperitoneally
administered MHC class I–deficient syngeneic lymphomas. (A) B6 mice
were injected intraperitoneally with 101–105 RMA-S, RMA-S-m144, or
RMA-S-neo tumor cells in 0.2 ml PBS. Mice were observed daily for tu-
mor growth up to 100 d by monitoring body weight and development of
ascites in mice. Individual mice are represented by each symbol and are
representative of three independent experiments. These data include mice
inoculated with one of four different RMA-S-m144–transfected clones.
(B) B6.P0 mice were inoculated with 101–105 tumor cells as above.
Figure 4. The lytic activity and accumulation of NK cells are reduced
in mice inoculated with RMA-S-m144 lymphoma cells. Mice were in-
jected intraperitoneally with PBS (white bars), RMA-S (103; black bars),
or RMA-S-m144 (103; striped bars) cells. 72 h later, the peritoneal lav-
ages were collected, and we recorded (a) total leukocyte numbers
(31025) and (b) total NK1.11 cell numbers (31023). The cells collected
from the lavage were incubated with 1,000 U/ml IL-2 overnight, and the
lytic activity of NK cells in the culture was determined by 51Cr-release as-
say against labeled YAC-1 targets and recorded as LU20/107 where 2 3
104 YAC-1 target cells were added per well at E/T ratios ranging from
200:1 to 1:1.439 Cretney et al.
was critical for m144-mediated protection and that acti-
vated, rather than unstimulated, NK cells may express the
m144 counterstructure. These data suggested that NK lysis
of class I–expressing target cells was not regulated by target
cell m144 expression. To reduce potential T-LAK–medi-
ated lysis in spleen NK cell cultures, spleen cells were ini-
tially depleted of Thy-1.21 T cells before IL-2 culture.
Cultures containing .95% IL-2–activated NK1.11 cells were
more lytic. Using this system, we also demonstrated that
m144 conferred some protection to RMA-S target cells
(Fig. 5 C). Potential nonspecific cytotoxicity by T cells and
NKT cells was also avoided by using IL-2–activated NK
cell cultures from B6.RAG-10 mice as effector cells. Once
again, m144 protected RMA-S-m144 target cells from lysis
mediated by IL-2–activated NK cells. Class I–expressing
target cells were not protected (Fig. 5 D).
Since mAbs that inhibit m144 function have not been
described and, in agreement with a previous study (17), the
15C6 anti-m144 mAb did not affect lysis of RMA-S-m144
target cells (data not shown), we examined the specificity
of m144 protection by cold target inhibition studies. Two
different assays were performed: in the first assay, equal
numbers of cold and 51Cr-labeled target cells were added to
effectors at a variety of E/T ratios (Fig. 6 A); in the second
assay, the number of labeled target cells was kept constant
and the competitor cold target cell number was varied (Fig.
6 B). In both assays, the lysis of 51Cr-labeled RMA-S target
cells was more effectively inhibited by the presence of cold
targets expressing m144 (Fig. 6, A and B). Based on the
similarity of MCMV m144 to MHC class I molecules, it
was possible that the cytoplasmic tail of m144 was affecting
the sensitivity of RMA-S target cells to cell death or simply
that the clones selected for m144 expression were also
more resistant to cell death. To test this possibility, RMA-S
and RMA-S-m144 cells were pulsed with human papil-
loma virus E749–57 peptide and exposed to cytotoxic CD81
T cells specific for this peptide (Fig. 7). Pulsed RMA-S and
RMA-S-m144 target cells were equally sensitive to E7-
specific CTL lysis, indicating that class I molecules could be
functional when loaded, irrespective of m144 expression,
and that m144 does not protect target cells from all forms
of cell-mediated death. Furthermore, in effector-free sys-
tems, RMA-S and RMA-S-m144 target cells were equally
sensitive to soluble FasL or perforin/granzyme B, the major
effector mechanisms used by CTLs and NK cells (data not
shown). Although these in vitro studies have demonstrated
a direct protective effect of m144 on NK cell–mediated ly-
sis, it is likely that a more significant role of m144 involves
the regulation of NK cell activation and accumulation
which in our studies correlated with resistance to tumor re-
jection.
Discussion
In this study, MCMV m144 was transfected into the
murine T lymphoma cell line RMA and its class I–deficient
derivative RMA-S. We have demonstrated that in vitro
m144 can directly inhibit cytolysis mediated by IL-2–acti-
vated NK cells, but this protection was only partial and re-
stricted to the activity of IL-2–activated NK cells against
class I–deficient target cells. More importantly, m144 pro-
tected RMA-S lymphoma cells from NK cell–mediated re-
Figure 5. MCMV m144 inhibits the cytotoxicity me-
diated by IL-2–activated NK cells. RMA-S (filled cir-
cles), RMA-S-m144 (open circles), RMA (filled trian-
gles), and RMA-m144 (open triangles) were labeled with
51Cr and used as targets in a standard 4-h 51Cr-release
assay. Effectors were generated from (A) whole resting
spleen cells from B6 mice, (B) IL-2 (1,000 U/ml)–acti-
vated (7 d) spleen cells from B6 mice, (C) anti–Thy-1
depleted and IL-2–activated (7 d) spleen cells from B6
mice, and (D) IL-2–activated (7 d) spleen cells from
B6.RAG-10 mice. E/T ratios were as shown with 2 3
104 labeled target cells/well. The spontaneous release of
51Cr was always ,15%, and all tests were performed in
triplicate. These assays were representative of at least
three different RMA-m144– and RMA-S-m144–trans-
fected clones and were repeated for A–D in two to three
experiments for each clone.440 m144 Protection from NK Cell–mediated Immune Responses
jection in vivo, a process that requires NK cell recruitment,
activation, and effector function. These data are the first to
demonstrate that m144 can, in isolation from other MCMV
proteins, regulate NK cell–mediated immune responses and
support our previous work that suggested that m144 can
prevent NK cell–mediated clearance of MCMV in vivo (11).
The dramatic effects of m144 expression on NK cell ac-
cumulation and rejection of RMA-S lymphoma cells in
vivo are unlikely to be explained by the comparatively mi-
nor protective effect of m144 against NK cell–mediated ly-
sis demonstrated in vitro. We have shown that m144 pro-
tected RMA-S lymphomas from NK cell–mediated rejection
in vivo by affecting the tumor rejection process at several
levels. m144 reduced the number of total leukocytes and
NK cells (by two- to threefold) recruited to the perito-
neum in response to tumor challenge. In addition, the
markedly reduced lytic capacity of NK cells recovered from
the peritoneum of RMA-S-m144–challenged mice suggests
that the activation of NK cells at the tumor site was also
decreased when m144 is expressed. Previous studies of
MCMV infection in the liver have indicated the impor-
tance of IL-12 for NK cell–mediated IFN-g production (2)
and macrophage inflammatory protein 1a (MIP-1a) for
NK cell infiltration (24). The key initial events involved in
recruitment of NK cells and other leukocytes in response
to peritoneal tumor challenge remain unclear. Previous ex-
periments using the RMA-S lymphoma have demonstrated
that T cells, B cells, F4/801 cells, and IL-12 are not critical
in effective NK cell–mediated rejection, but that TNF is
important for NK cells to effectively accumulate in re-
sponse to RMA-S tumor challenge in the peritoneum (21).
Therefore, we favor the possibility that a local interaction
between APCs, NK cells, and stromal elements leads to the
development of a cytokine/chemokine network that regu-
lates the innate response to tumor. This model would pre-
dict that m144 may interact with an inhibitory receptor on
local APCs, ultimately reducing APC cytokine/chemokine
secretion and therefore NK cell activation. Leong et al. (25)
have suggested that the human CMV class I homologue,
UL18, might function in such a manner, a suggestion sup-
ported by the ability of UL18-Fc fusion proteins to bind
Figure 7. CTL-mediated cytotox-
icity of lymphoma cells is unaffected
by m144 expression. RMA-S (filled
circles) and RMA-S-m144 (open cir-
cles) were labeled with 51Cr and used
as targets in a standard 4-h 51Cr-
release assay. In some wells, RMA-S
or RMA-S-m144 cells had been
prepulsed with E749–57 or OVA257–264
peptide. Effector cells were generated
from the spleens of E7-immunized
B6 mice as described previously (ref-
erence 21). E/T ratios were as shown
with 2 3 104 labeled target cells/well.
The spontaneous release of 51Cr was
always ,15%, and all tests were per-
formed in triplicate. These results are
representative of at least two different
RMA-S-m144 clones.
Figure 6. Competitive inhibition of NK cell–mediated cytotoxicity.
RMA-S (filled circles) and RMA-S-m144 (open circles) were labeled
with  51Cr and used as targets in a standard 4-h 51Cr-release assay. Effectors
were generated from IL-2 (1,000 U/ml)–activated (7 d) spleen cells from
B6 mice. In A, an equal number of 51Cr-labeled RMA-S targets and
competitor unlabeled RMA-S (filled triangles) or RMA-S-m144 (open
triangles) targets were added (ratio relative to number of 51Cr-labeled tar-
gets). In B, an increasing number of cold RMA-S or RMA-S-m144 tar-
get cells were added as indicated to 51Cr-labeled RMA-S target cells fixed
at a ratio of 100:1 (effector/51Cr-labeled target/unlabeled target ratio
shown). The spontaneous release of 51Cr was always ,15%, and all tests
were performed in triplicate. These results are representative of two ex-
periments.441 Cretney et al.
leukocyte Ig-like receptor (LIR-1) expressed predomi-
nantly on B cells and monocytes and a small population of
NK cells (26). It has also been noted that the subpopulation
with the highest LIR-1 expression is a major source of
IFN-a, a potent NK cell stimulus (27). Although studies
with the closest murine homologue of LIR-1 have not re-
vealed binding to m144 (Chapman, T., unpublished data),
we cannot exclude the possibility that m144 does interact
with an inhibitory receptor on a cell that is normally the
source of cytokines essential for NK cell activation. The
observation that m144 did not protect RMA-m144 lym-
phoma cells from rejection indicates that m144 specifically
regulates those immune responses critical for NK cell–
mediated tumor rejection. m144 did not alter rejection of
RMA-S tumor in B6.P0 mice simply because NK cells ex-
clusively use perforin to reject RMA-S lymphoma from
the peritoneum (21), and thus NK cell responses to paren-
tal RMA-S are completely abrogated in B6.P0 mice.
Our in vitro studies demonstrated that m144 was able to
inhibit direct syngeneic NK cell–mediated cytotoxicity.
Nevertheless, the level of protection afforded was never
complete and was only observed in cultures where nonre-
stricted lysis of class I–expressing target cells was low. In
some cultures using whole spleen cells activated with IL-2
as effectors, lysis of RMA cells was comparable to lysis of
RMA-S cells, and m144 expression afforded no protection
to RMA-S-m144 transfectants (data not shown). These
data contrast with the complete protection mouse CD1.1
afforded RMA-S cells from A-LAK cytotoxicity (16). It is
likely that the relative concentration of the appropriate
ligand on the effector NK cells may explain these differ-
ences, since selected late-adhering A-LAK cultures (16) are
more homogeneous than the IL-2–activated spleen cultures
we have used. In this context, it is possible that only those
NK cells expressing relatively high levels of the putative
m144 ligand receive the m144 inhibitory signal. Alterna-
tively, in the absence of data relating to the level of m144
expression on the surface of MCMV-infected cells, it is
possible to postulate that the levels of m144 expression on
RMA-S target cells may be too low to deliver inhibitory
signals to all NK cells. Clearly however, m144 offered no
protection from cytotoxicity mediated by unstimulated
spleen NK cells, suggesting that the m144 ligand may be
scarce or conformationally inactive on resting NK cells.
Since m144 had no effect on the lysis of RMA cells, the
m144 ligand may be absent on NK cells that are not inhib-
ited by target cell class I expression. From preliminary stud-
ies, m144 is not delivering an apoptotic signal to activated
NK cells (data not shown).
The TAP-2–deficient cell line RMA-S can present pep-
tides derived from cytosolic proteins on classical MHC class
I through a TAP-independent pathway (28). Thus, it could
be argued that the protective effect seen in RMA-S-m144
is actually mediated by m144-derived peptides stabilizing
normally thermally unstable Db and Kb molecules expressed
by RMA-S. Evidence against this argument is provided by
the finding that no reproducible increase in cell surface ex-
pression of Db and Kb was detected in RMA-S-m144
transfectants. Furthermore, given that murine class I Qa-1b
can present leader sequences from murine class Ia molecules
and may bind inhibitory CD94/NKG2A heterodimers (29,
30), it is possible that m144 inhibition of NK cell–mediated
lysis is actually mediated by Qa-1b. However, the leader se-
quence of m144 does not contain the necessary motif to
bind Qa-1b. Alternatively, as RMA-S cells transfected with
CD1d have been demonstrated to inhibit NK cell cytotox-
icity (16), it may be argued that this molecule (which is
normally expressed at low levels in RMA-S cells) may be
involved in the protective effects of m144. However, ex-
pression of m144 on RMA-S cells did not appear to upreg-
ulate Cd1d expression, indicating that the protection con-
ferred by m144 was CD1d independent.
In summary, MCMV m144 conferred some protection
from NK cell effector function mediated in the absence of
target cell class I expression, but in vivo the major effect of
m144 was to regulate NK cell accumulation and activation
at the site of tumor challenge. It remains to be determined
whether inhibiting NK cell activation and accumulation is
the principal role of m144 during viral infection. However,
infections comparing wild-type and m144-deficient strains
of MCMV suggested that the activation of NK cytolysis in
situ was inhibited .10-fold in the presence of m144 (data
not shown). The cytokine- and cytotoxicity-mediated mech-
anisms of virus clearance by NK cells have been shown to
play different roles in different organs of the infected ani-
mal (31). It is possible that the m144 molecule may func-
tion during infection to inhibit both mechanisms of NK
cell–mediated clearance of virus in vivo. Identification and
characterization of the MCMV m144 ligand(s) and the leu-
kocyte subsets that are regulated by m144 expression will
greatly improve our understanding of MCMV evasion of
host immune responses and will clarify the relationships be-
tween NK and other innate immune cells.
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